The IDWeek 2018 conference was held in San Francisco, USA, from 3-7 October 2018.

Conference highlights

Treatment simplification strategies

Studies confirm long-term effectiveness of new single-tablet regimens.

Hepatitis C symptoms and diagnosis

Majority of US young adults who use drugs are not tested for hepatitis C or HIV.

New and experimental HIV treatments

Doravirine combination works well as a switch option.

aidsmap news

There is no aidsmap news from IDWeek 2018 yet. Showing all aidsmap news instead.

Editors' picks from other sources

There are no Editors' Picks from IDWeek 2018 yet. Showing all Editors' picks instead.

News bulletins

Sign up for our email bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Official conference website

Find out more on the official conference website.

Visit the IDWeek website >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.